Life Sciences & Healthcare

Insights and learnings for Japanese life sciences organisations that are globalising to fulfil growth ambitions. Driven by domestic economic and industry-specific challenges, many Japan-headquartered life sciences organisations are looking at greater globalisation as a catalyst for growth and innovation. This report highlights this trend via executive interviews across Japanese life sciences (LS) organisations, non-Japanese LS organisations, and cross-industry Japanese organisations.

Our 15th year analysing the forecast average internal rate of return (IRR) for the top 20 biopharma companies reveals a second year of growth to 5.9 per cent in 2024. Discover more.

Welcome to the fourth of a series of life sciences and healthcare predictions reports, comprising ten predictions exploring how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs our views of tomorrow and how AI technologies, specifically GenAI, might help to bring the future closer.

The Future of Health Series is a dynamic collection of webcasts designed to spark conversations and drive meaningful change across the health care landscape.

In this report, Project HOPE and Deloitte US have brought together frontline health care workers, programme leaders, health system advisors, policy and advocacy professionals, community leaders, and strategic relationships to collaborate on potential solutions for enhancing climate resilience.

Platform businesses are rewiring the traditional value chain. In nearly every industry, well-thought-out platform businesses typically beat traditional businesses because of superior unit economics and network effects.

From digital health to biotech and from digital therapeutics to health care IT innovations, there’s a community and a conversation about it at HLTH Europe event.